06 Jul 2017
N+1 Singer - Oxford BioMedica - New Novartis supply agreement in anticipation of CTL019 launch
The new agreement with Novartis for the commercial and clinical supply of lentiviral vectors is very encouraging and builds on the existing relationship. Oxford BioMedica will receive a $10m upfront payment and could potentially receive in excess of $100m from Novartis over the next three years. The new supply agreement has been established in anticipation of the potential commercial launch of CTL019 for the treatment of acute lymphoblastic leukaemia. We had assumed Novartis would establish a ne ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Oxford BioMedica - New Novartis supply agreement in anticipation of CTL019 launch
Oxford BioMedica plc (OXB:LON) | 204 0 0.0% | Mkt Cap: 203.5m
- Published:
06 Jul 2017 -
Author:
Sheena Berry -
Pages:
3
The new agreement with Novartis for the commercial and clinical supply of lentiviral vectors is very encouraging and builds on the existing relationship. Oxford BioMedica will receive a $10m upfront payment and could potentially receive in excess of $100m from Novartis over the next three years. The new supply agreement has been established in anticipation of the potential commercial launch of CTL019 for the treatment of acute lymphoblastic leukaemia. We had assumed Novartis would establish a ne ....